Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Bevacizumab with or without Gemcitabine in Metastatic Pancreatic Cancer
NCT00326911Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, bevacizumab, sponsored by Eli Lilly and Company. Started May 2006; status: terminated.
02
Drugs
KL-140bevacizumab
Beyond the preview
Go deeper on NCT00326911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326911.